Rotigotine
From Wikipedia, the free encyclopedia
 |
|
|
Rotigotine
|
|
| Systematic (IUPAC) name | |
| 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol | |
| Identifiers | |
| CAS number | 92206-54-7 |
| ATC code | N04BC09 |
| PubChem | 57537 |
| Chemical data | |
| Formula | C19H25NOS |
| Mol. weight | 315.474 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 37% (transdermal) |
| Protein binding | 92% |
| Metabolism | Hepatic (CYP-mediated) |
| Half life | 5 to 7 hours |
| Excretion | Renal (71%) and fecal (23%) |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
? |
| Legal status |
POM(UK) |
| Routes | Transdermal patch |
Rotigotine is a non-ergoline dopamine agonist drug developed by Aderis Pharmaceuticals for the treatment of Parkinson's disease. Rotigotine is intended to be delivered through transdermal patches, so as to ensure a slow and constant dosage in a 24 hour period. The transdermal patch form of the drug has been given the trade name Neupro. The starter pack is being sold under prescription for about 680 USD and it comes with 28 patches of 2, 4, 6, and 8 mg to help doctors and patients find the correct dosage.
The drug has been approved by the EMEA for use in some European countries and Australia, and is today being sold under the German owned brand of Schwarz Pharma AG; the legal owner of the patch since 2005. As of 2006, the phase III clinical trial results showed that the drug was able to significantly reduce off time and increase on time without troublesome dyskinesia. The patch is under trial waiting for Food and Drug Administration (FDA) approval in the United States. The nasal spray version of the drug is in phase II waiting for results at the end of 2006. Once estimated the correct patch dosage needed the packages can be bought in quantities of 28, 56, or 84 at an average price of about 17 to 30 USD a patch depending on the dosage.
[edit] See also
[edit] External links
- Manufacturer's webpage for rotigotine
- BBC News article: Skin patch hope for Parkinson's
- Medscape article: Transdermal Rotigotine Patch Safe, Effective in Early Idiopathic Parkinson's Disease
- Bandolier article: Rotigotine for restless legs syndrome - concludes that there is insufficient evidence for the use of rotigotine for treating RLS
- Owner's webpage for Neupro
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
